Physician profile
Ashley Mathai
NPI 1306330295
$7,906.86
in general payments reported to CMS, 2019-2025
17 companies · $2,336 in 2025
The $2,336 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,664 · 2022: $1,731 · 2023: $854 · 2024: $1,323 · 2025: $2,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,512.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,666.74 | 2021-2025 | Ingrezza |
| Abbvie INC. | $1,575.27 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,402.78 | 2021-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $789.78 | 2021-2025 | Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $629.18 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $363.22 | 2024-2025 | Auvelity, Symbravo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $262.12 | 2021-2022 | |
| Lundbeck LLC | $260.24 | 2021-2023 | Rexulti |
| Pfizer INC. | $239.21 | 2025 | |
| Janssen Pharmaceuticals, INC | $178.90 | 2021-2022 | |
| Alkermes, INC. | $172.30 | 2021-2022 | |
| Gilead Sciences, INC. | $130.16 | 2022-2024 | Biktarvy |
| Glaxosmithkline, LLC. | $124.12 | 2021 | |
| Almatica Pharma LLC | $52.62 | 2022 | |
| Sunovion Pharmaceuticals INC. | $23.92 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $21.74 | 2022 | |
| Indivior INC. | $14.56 | 2023 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mathai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.